Drug Trial Radar · NCT05423691
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 27, 2022
Primary completion
Apr 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Cellenkos, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Conditions
- Myelofibrosis
Interventions
CK0804Drug
CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine Treatment limiting toxicity (TLT) as defined belowTime frame: 28 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
UC Davis Health
Sacramento, California · Recruiting
Columbia University
New York, New York · Not yet recruiting
Montefiore Einstein Cancer Center
The Bronx, New York · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.